Target intelligence / Profile preview

Human endogenous retrovirus K envelope protein (HERV-K Env)

Target
HERV-K Env
Molecular classification
Retroviral envelope protein, Viral protein, Tumor-associated antigen
01

Overview

Human endogenous retrovirus K (HERV-K) envelope protein is a protein product of ancient retroviral sequences integrated into the human genome, specifically the HML-2 family. While typically silenced in healthy adult tissues, HERV-K Env is frequently reactivated and overexpressed in various malignancies, including melanoma, breast, and prostate cancers, where it contributes to tumor progression, cell fusion, and immune evasion. In neurological contexts, particularly amyotrophic lateral sclerosis (ALS), the aberrant expression of HERV-K Env has been linked to neurotoxicity and motor neuron damage. Therapeutic strategies targeting this antigen include monoclonal antibodies designed to neutralize its pathogenic effects, as well as antiretroviral drugs aimed at suppressing its transcription and replication. As a tumor-associated antigen, it is also being explored as a target for cancer vaccines and T-cell-based immunotherapies.

Other names
HERV-K envelope proteinHERV-K(HML-2) envelope proteinHuman endogenous retrovirus K antigenHERV-K Env proteinHML-2 Env
02

Mechanism of action

Neutralization of pathogenic envelope proteins to inhibit neuroinflammation and demyelination; inhibition of retroviral reverse transcription and integration to reduce HERV expression; induction of immune response against tumor cells expressing HERV antigens.

03

Biological functions

Cell-cell fusionImmune modulationSignal transductionViral mimicryOncogenesis
04

Disease associations

CancerMelanomaBreast cancerProstate cancerAmyotrophic lateral sclerosis (ALS)HIV infection
05

Safety considerations

Potential for autoimmune cross-reactivity due to molecular mimicryVariable expression levels in normal tissues (e.g., placenta)Low receptor density on tumor surfaces for certain modalities like ADCs
06

Interacting drugs

Temelimab (GNbAC1)

3 more in the full profile.

07

Biomarkers

HERV-K Env expressionHERV-K RNA levelsAnti-HERV-K antibody titers

Beyond the preview

Go deeper on Human endogenous retrovirus K envelope protein (HERV-K Env).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human endogenous retrovirus K envelope protein (HERV-K Env).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call